Psoriasis Clinical Trial

Clinical Trial Finder Psoriasis Trials

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

See Locations Near You

Summary

This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients who have completed the entire treatment period of the 24 week core study

Exclusion Criteria:

Inability or unwillingness to undergo repeated subcutaneous injections; inability to comply with study or follow-up procedures; any medical or psychiatric condition which, in the investigator's opinion wouldpreclude the participant from adhering to the protocol or completing the study per protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

86

Study ID:

NCT01090310

Recruitment Status:

Terminated

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 35 Locations for this study

See Locations Near You

Novartis Investigative Site
Beverly Hills California, 90211, United States
Novartis Investigative Site
Atlanta Georgia, 30322, United States
Novartis Investigative Site
Louisville Kentucky, 40202, United States
Novartis Investigative Site
Baltimore Maryland, 21205, United States
Novartis Investigative Site
Cambridge Massachusetts, 02142, United States
Novartis Investigative Site
Teaneck New Jersey, 07666, United States
Novartis Investigative Site
Charlotte North Carolina, 28210, United States
Novartis Investigative Site
Portland Oregon, 97239, United States
Novartis Investigative Site
Arlington Texas, 76012, United States
Novartis Investigative Site
Houston Texas, 77025, United States
Novartis Investigative Site
Sao Paulo SP, 05403, Brazil
Novartis Investigative Site
São Paulo SP, 04023, Brazil
Novartis Investigative Site
Berlin , 13353, Germany
Novartis Investigative Site
Kiel , 24105, Germany
Novartis Investigative Site
Tübingen , 72076, Germany
Novartis Investigative Site
New Delhi , 110 0, India
Novartis Investigative Site
Jerusalem , 91120, Israel
Novartis Investigative Site
Petach Tikva , 49100, Israel
Novartis Investigative Site
Ramat Gan , 52662, Israel
Novartis Investigative Site
Tel-Aviv , 64239, Israel
Novartis Investigative Site
Barcelona Catalunya, 08035, Spain
Novartis Investigative Site
Barcelona Catalunya, 08036, Spain
Novartis Investigative Site
Santiago de Compostela Galicia, 15705, Spain
Novartis Investigative Site
Madrid , 28040, Spain
Novartis Investigative Site
Lausanne CHE, 1004, Switzerland
Novartis Investigative Site
Bern , 3010, Switzerland
Novartis Investigative Site
Bern , 3012, Switzerland
Novartis Investigative Site
Lausanne , 1003, Switzerland
Novartis Investigative Site
Luzern , 6000, Switzerland
Novartis Investigative Site
St. Gallen , 9007, Switzerland
Novartis Investigative Site
Zuerich , 8063, Switzerland
Novartis Investigative Site
Birmingham , B18 7, United Kingdom
Novartis Investigative Site
Liverpool , L7 8X, United Kingdom
Novartis Investigative Site
London , SE1 7, United Kingdom
Novartis Investigative Site
York , YO31 , United Kingdom
Load More

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

86

Study ID:

NCT01090310

Recruitment Status:

Terminated

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider